Equity research analysts tracking Puma Biotechnology, Inc. (NASDAQ: PBYI) evaluate its commercialized targeted breast cancer therapy, Nerlynx, alongside its ongoing clinical trials. Consensus price targets from small-cap healthcare analysts fluctuate based on quarterly prescription sales volumes and clinical data milestones, requiring investors in micro-cap and small-cap biotech equities to perform rigorous due diligence regarding cash runway and commercial uptake.